206 related articles for article (PubMed ID: 30623789)
1. Multifunctional nanoparticles based on a polymeric copper chelator for combination treatment of metastatic breast cancer.
Zhou P; Qin J; Zhou C; Wan G; Liu Y; Zhang M; Yang X; Zhang N; Wang Y
Biomaterials; 2019 Mar; 195():86-99. PubMed ID: 30623789
[TBL] [Abstract][Full Text] [Related]
2. Dual pH-responsive multifunctional nanoparticles for targeted treatment of breast cancer by combining immunotherapy and chemotherapy.
Liu Y; Qiao L; Zhang S; Wan G; Chen B; Zhou P; Zhang N; Wang Y
Acta Biomater; 2018 Jan; 66():310-324. PubMed ID: 29129789
[TBL] [Abstract][Full Text] [Related]
3. TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy.
Rodell CB; Arlauckas SP; Cuccarese MF; Garris CS; Li R; Ahmed MS; Kohler RH; Pittet MJ; Weissleder R
Nat Biomed Eng; 2018 Aug; 2(8):578-588. PubMed ID: 31015631
[TBL] [Abstract][Full Text] [Related]
4. Toll-like receptor 7/8 agonist R848 alters the immune tumor microenvironment and enhances SBRT-induced antitumor efficacy in murine models of pancreatic cancer.
Ye J; Mills BN; Qin SS; Garrett-Larsen J; Murphy JD; Uccello TP; Han BJ; Vrooman TG; Johnston CJ; Lord EM; Belt BA; Linehan DC; Gerber SA
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35851308
[TBL] [Abstract][Full Text] [Related]
5. Intratumoral immunotherapy using platelet-cloaked nanoparticles enhances antitumor immunity in solid tumors.
Bahmani B; Gong H; Luk BT; Haushalter KJ; DeTeresa E; Previti M; Zhou J; Gao W; Bui JD; Zhang L; Fang RH; Zhang J
Nat Commun; 2021 Mar; 12(1):1999. PubMed ID: 33790276
[TBL] [Abstract][Full Text] [Related]
6. The Remarkable Anti-Breast Cancer Efficacy and Anti-Metastasis by Multifunctional Nanoparticles Co-Loading Squamocin, R848 and IR 780.
Wang X; Liu X; Guo Y; Gong T; Lu W; Han M; Guo Y; Wang X
Int J Nanomedicine; 2024; 19():4679-4699. PubMed ID: 38803997
[TBL] [Abstract][Full Text] [Related]
7. Peptide-guided resiquimod-loaded lignin nanoparticles convert tumor-associated macrophages from M2 to M1 phenotype for enhanced chemotherapy.
Figueiredo P; Lepland A; Scodeller P; Fontana F; Torrieri G; Tiboni M; Shahbazi MA; Casettari L; Kostiainen MA; Hirvonen J; Teesalu T; Santos HA
Acta Biomater; 2021 Oct; 133():231-243. PubMed ID: 33011297
[TBL] [Abstract][Full Text] [Related]
8. Dual-Functional PLGA Nanoparticles Co-Loaded with Indocyanine Green and Resiquimod for Prostate Cancer Treatment.
Lin W; Li C; Xu N; Watanabe M; Xue R; Xu A; Araki M; Sun R; Liu C; Nasu Y; Huang P
Int J Nanomedicine; 2021; 16():2775-2787. PubMed ID: 33880023
[TBL] [Abstract][Full Text] [Related]
9. TLR7 and TLR8 agonist resiquimod (R848) differently regulates MIF expression in cells and organs.
Adzavon YM; Zhao P; Lv B; Liu M; Zhang X; Xie F; Yang L; Shang L; Zhang M; Li Q; Ma X
Cytokine; 2017 Sep; 97():156-166. PubMed ID: 28648870
[TBL] [Abstract][Full Text] [Related]
10. Development of resiquimod-loaded modified PLA-based nanoparticles for cancer immunotherapy: A kinetic study.
Thauvin C; Widmer J; Mottas I; Hocevar S; Allémann E; Bourquin C; Delie F
Eur J Pharm Biopharm; 2019 Jun; 139():253-261. PubMed ID: 30981947
[TBL] [Abstract][Full Text] [Related]
11. An Intelligent Biomimetic Nanoplatform for Holistic Treatment of Metastatic Triple-Negative Breast Cancer
Cheng Y; Chen Q; Guo Z; Li M; Yang X; Wan G; Chen H; Zhang Q; Wang Y
ACS Nano; 2020 Nov; 14(11):15161-15181. PubMed ID: 33143424
[TBL] [Abstract][Full Text] [Related]
12. Dual activation of Toll-like receptors 7 and 9 impairs the efficacy of antitumor vaccines in murine models of metastatic breast cancer.
Moreno Ayala MA; Gottardo MF; Gori MS; Nicola Candia AJ; Caruso C; De Laurentiis A; Imsen M; Klein S; Bal de Kier Joffé E; Salamone G; Castro MG; Seilicovich A; Candolfi M
J Cancer Res Clin Oncol; 2017 Sep; 143(9):1713-1732. PubMed ID: 28432455
[TBL] [Abstract][Full Text] [Related]
13. Polydopamine-coated ferric oxide nanoparticles for R848 delivery for photothermal immunotherapy in breast cancer.
Yuan Z; He H; Zou J; Wang H; Chen Y; Chen Y; Lan M; Zhao Y; Gao F
Int J Pharm; 2023 Sep; 644():123249. PubMed ID: 37467816
[TBL] [Abstract][Full Text] [Related]
14. Development of Adamantane-Conjugated TLR7/8 Agonists for Supramolecular Delivery and Cancer Immunotherapy.
Rodell CB; Ahmed MS; Garris CS; Pittet MJ; Weissleder R
Theranostics; 2019; 9(26):8426-8436. PubMed ID: 31879528
[TBL] [Abstract][Full Text] [Related]
15. Photothermally activatable PDA immune nanomedicine combined with PD-L1 checkpoint blockade for antimetastatic cancer photoimmunotherapy.
Lu Q; Qi S; Li P; Yang L; Yang S; Wang Y; Cheng Y; Song Y; Wang S; Tan F; Li N
J Mater Chem B; 2019 Apr; 7(15):2499-2511. PubMed ID: 32255127
[TBL] [Abstract][Full Text] [Related]
16. The TLR7/8 agonist R848 optimizes host and tumor immunity to improve therapeutic efficacy in murine lung cancer.
Zhou J; Xu Y; Wang G; Mei T; Yang H; Liu Y
Int J Oncol; 2022 Jul; 61(1):. PubMed ID: 35552764
[TBL] [Abstract][Full Text] [Related]
17. Formulation and preclinical evaluation of a toll-like receptor 7/8 agonist as an anti-tumoral immunomodulator.
Lu R; Groer C; Kleindl PA; Moulder KR; Huang A; Hunt JR; Cai S; Aires DJ; Berkland C; Forrest ML
J Control Release; 2019 Jul; 306():165-176. PubMed ID: 31173789
[TBL] [Abstract][Full Text] [Related]
18. Targeting Toll-like receptor 7/8 enhances uptake of apoptotic leukemic cells by monocyte-derived dendritic cells but interferes with subsequent cytokine-induced maturation.
van den Ancker W; van Luijn MM; Ruben JM; Westers TM; Bontkes HJ; Ossenkoppele GJ; de Gruijl TD; van de Loosdrecht AA
Cancer Immunol Immunother; 2011 Jan; 60(1):37-47. PubMed ID: 20859626
[TBL] [Abstract][Full Text] [Related]
19. TLR7/8 Agonist-Loaded Nanoparticles Augment NK Cell-Mediated Antibody-Based Cancer Immunotherapy.
Kim H; Khanna V; Kucaba TA; Zhang W; Sehgal D; Ferguson DM; Griffith TS; Panyam J
Mol Pharm; 2020 Jun; 17(6):2109-2124. PubMed ID: 32383885
[TBL] [Abstract][Full Text] [Related]
20. Combining vasculature disrupting agent and Toll-like receptor 7/8 agonist for cancer therapy.
Seth A; Lee H; Cho MY; Park C; Korm S; Lee JY; Choi I; Lim YT; Hong KS
Oncotarget; 2017 Jan; 8(3):5371-5381. PubMed ID: 28036266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]